Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email :mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories announces the launch of Versavo (bevacizumab biosimilar) in India"
This is for your information.
| /s/ Vikas Sabharwal | |
| Vikas Sabharwal | |
| Assistant Company Secretary | |
| Encl: As above | |
| CC:- New York Stock Exchange Inc.(Stock Code :RDY) |
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40- 49002121) |
Dr. Reddy's Laboratories
the launch of Versavo
(bevacizumab biosimilar) in India
Hyderabad, India, August 19, 2019 - Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Versavo (bevacizumab),
a biosimilar of Roche's Avastin in India, indicated for the treatment of several types of cancers (metastatic
colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer,
metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer).
Dr. Reddy's Versavo is available in strengths
of 100mg and 400mg single use vials.
Commenting on the launch, MV Ramana, CEO - India and Emerging
Markets, Dr. Reddy's Laboratories, said, "We regard the good health of our patients as our responsibility and are committed
to ensure that they always have access to the medicines they need. The launch of Versavo is another step in that
journey and helps strengthen our Oncology portfolio."
Dr. Raymond De Vr , Global Head, Biologics, Dr. Reddy's
Laboratories added "Versavo will help improve access to high quality therapy at an affordable cost, addressing
the needs of patients with different cancers in India."
Avastin and its biosimilars had India sales
of approximately INR 223 Crore MAT for the most recent twelve months ending in December 2018, according to Ipsos*.
Dr. Reddy's now has six biosimilar products commercialized
in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology
*Ipsos India Tandem Oncology Monitor 2018
That the biological product is highly similar to the reference
product notwithstanding minor differences in clinically inactive components; and,
There are no clinically meaningful differences between the biological
product and the reference product in terms of the safety, purity, and potency of the product.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &
Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas
of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates
in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information